Rhythm Pharmaceuticals Inc (1RV F) stock market data APIs
€86.361
0.19(0.2%)
as of October 13, 2025
Try our APIs with
free plan!
Rhythm Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
Prev. Close
86.361
Open
86.555
High
86.555
Low
86.361
52 wk Range
41-89
Market Cap
5 792 M
Shares Outstanding
66 420 K
Revenue
156 M
EPS
-0.75
Beta
2.123
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Rhythm Pharmaceuticals Inc data using free add-ons & libraries
Get Rhythm Pharmaceuticals Inc Fundamental Data
Rhythm Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 156 M
- EBITDA: -175 910 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-05
- EPS/Forecast: -0.67
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Rhythm Pharmaceuticals Inc News
New
Rhythm Pharma Stock Gears Up For Its Next Move
Rhythm Pharmaceuticals formed a flat base after pulling back from a record high in early September. Rhythm Pharma develops treatments for rare neuroendocrine diseases and is Thursday's pick for IBD 50...
Should You Expect Robust Growth Potential for Rhythm Pharmaceuticals (RYTM) Ahead?
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Eq...
Nvidia, These Other AI Plays Lead 5 Stocks Near Buy Points
Three of the five stocks to watch are part of the artificial intelligence trade, including chip company Nvidia. Continue Reading View Comments
3 Stocks That May Be Undervalued By Up To 49%
As U.S. stock indexes, including the Dow, S&P 500, and Nasdaq, continue to reach new all-time highs amid significant partnerships like Nvidia's with OpenAI, investors are keenly observing market dynam...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
